ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and investor conferences in September 2026 in New York, including events hosted by Cantor, Moody Capital, H.C.

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and investor conferences in September 2026 in New York, including events hosted by Cantor, Moody Capital, H.C. Wainwright and Roth, plus a World Alzheimer’s Day appearance at the Nasdaq Tower on September 21.

Company executives Neil Warma (President & CEO), Dr. Larry Altstiel (CMO) and Carie Pierce (VP, Investor Relations & External Affairs) will discuss the EpiSelect™ platform, ProMIS’ approach to targeting toxic misfolded proteins in neurodegenerative diseases, and PMN310, its lead asset in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease. ProMIS recently reported blinded 6‑month interim data from this fully enrolled trial, with 12‑month topline data expected in early 2027. Webcast links and replays will be available via the Investors section of the company’s website.

Argus Sep 1 session 5 alerts

+3.60% close to close 6.6x rel. volume Open Argus

Details

News Market Reaction – PMN

-8.9% Trough in 27 min

$131.47M Market Cap

In the Sep 1 session, PMN gained 3.60%, reflecting a moderate positive market reaction. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 6.6x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

2,280 shares were purchased by Chief Development Officer Johanne Kaplan in the recent Form 4 record....

Analysis

2,280 shares were purchased by Chief Development Officer Johanne Kaplan in the recent Form 4 record. That insider activity adds context to the conference schedule, while the active S-3 shelf remains a financing risk.

Key Figures

Cantor conference dates: September 9-11, 2026 Moody Capital conference dates: September 9-10, 2026 H.C. Wainwright conference dates: September 14-16, 2026 +5 more

Cantor conference dates

September 9-11, 2026

Upcoming conference participation

Moody Capital conference dates

September 9-10, 2026

Upcoming conference participation

H.C. Wainwright conference dates

September 14-16, 2026

Upcoming conference participation

World Alzheimer’s Day event

September 21, 2026

Nasdaq Tower event

Roth conference date

September 29, 2026

Upcoming conference participation

Interim data timing

6-month

Blinded PRECISE-AD Phase 1b interim data reported in July 2026

Topline data timing

12-month

PRECISE-AD data anticipated in early 2027

Trial phase

Phase 1b

Ongoing PRECISE-AD trial in early Alzheimer’s disease

Historical Context

5 past events · Latest: Aug 13

5 events

1. Aug 13

   2Q26 earnings report

   24h Move

   +0.2%

   Quarterly results included clinical updates, cash runway, and a reported net loss.

2. Aug 03

   Earnings date notice

   24h Move

   -4.0%

   The company scheduled its second-quarter results and business update for August 13.

3. Jul 28

   Phase 1b clinical data

   24h Move

   +23.9%

   Six-month blinded safety and biomarker data reported no ARIA-E cases.

4. Jul 27

   Phase 1b data webinar

   24h Move

   +23.9%

   The company announced a webinar covering upcoming interim trial data.

5. Jul 14

   Clinical data update

   24h Move

   +6.7%

   Human data showed dose-dependent amyloid-beta oligomer reductions after PMN310 dosing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

misfolded proteins, phase 1b, blinded interim data

3 terms

misfolded proteins medical

"targeting toxic misfolded proteins in neurodegenerative diseases"

Proteins that have adopted an abnormal three‑dimensional shape so they no longer perform their normal function and often stick together inside or between cells. Think of a folded paper that is creased wrong and can’t be used as intended; misfolded proteins can disrupt cell processes and trigger disease pathways. They matter to investors because many diagnostics and drug programs target these proteins, so scientific or regulatory news about them can influence a biomedical company’s development prospects and market value.

phase 1b medical

"PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

blinded interim data medical

"ProMIS reported blinded 6-month interim data from its fully enrolled"

Data collected and analyzed partway through a clinical trial where identifying information about which participants received the active treatment or placebo has been hidden (blinded). It lets sponsors, monitors, or independent committees check safety, enrollment, or broad outcome trends without revealing treatment assignments, preserving the trial’s scientific integrity; investors care because such updates can give early signals about progress or safety while remaining provisional and not conclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

Conference details below:

September 9-11: Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET
Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer
Webcast link: Click Here

September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference
Location: New York, NY
Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1
Webcast link: Click Here

September 14-16: H.C. Wainwright 28^th Annual Global Investment Conference
Location: New York, NY
Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4^th floor)
Webcast link: Click Here

September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower
Location: Nasdaq Tower, New York, NY

September 29: Roth Healthcare Opportunities Conference
Location: New York, NY

During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.

ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.

Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website. Click Here

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Investor Relations Contact:

Carie Pierce, VP, Investor Relations & External Affairs

IR@promisneurosciences.com

FAQ

What conferences will ProMIS Neurosciences (PMN) attend in September 2026?

ProMIS Neurosciences will attend the Cantor Global Healthcare, Moody Capital Disruptive Growth & Life Sciences, H.C. Wainwright Global Investment, and Roth Healthcare Opportunities conferences in September 2026 in New York. According to ProMIS, these events include fireside chats and company presentations for investors.

When will ProMIS Neurosciences (PMN) present at the Cantor Global Healthcare Conference 2026?

ProMIS Neurosciences will hold a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, from 9:10 to 9:40 a.m. ET. According to ProMIS, Cantor analyst Pete Stavropoulos will speak with President & CEO Neil Warma.

What will ProMIS Neurosciences discuss about PMN310 and the PRECISE-AD trial in September 2026 events?

ProMIS will discuss PMN310, its lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease. According to ProMIS, blinded 6‑month interim data were reported in July 2026, with 12‑month topline results anticipated in early 2027.

How is ProMIS Neurosciences (PMN) recognizing World Alzheimer’s Day in 2026?

On September 21, 2026, World Alzheimer’s Day, ProMIS Neurosciences and Nasdaq will mark the occasion at the Nasdaq Tower in New York. According to ProMIS, this event complements the company’s focus on therapeutics for neurodegenerative diseases, including early Alzheimer’s disease.

Will webcasts or replays be available for ProMIS Neurosciences’ September 2026 conference presentations?

Yes, webcast replays of the upcoming September 2026 presentations will be available. According to ProMIS, investors can access these replays, as well as the interim PRECISE‑AD data webinar, in the Investors section of the company’s website via posted links.

Who will represent ProMIS Neurosciences (PMN) at the September 2026 investor conferences?

ProMIS will be represented by Neil Warma, President & CEO, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs. According to ProMIS, they will present the EpiSelect™ platform and the company’s neurodegenerative disease pipeline.